March 2014
January 2014
EMA >> Committees >> CHMP>> Agendas, minutes and highlights
May 2014
June 2014
July 2014
2013
LEMTRADA Alentuzumab (anti-CD52) Relapsing remitting MS
REMSIMA
INFLECTRAInfliximab (anti-TNF) Same indications as Remicade
KADCYLA Trastuzumab emtansine HER2-positive breast cancer
2014
SYLVANT Siltuximab (anti-IL-6) Multicentric Castleman’s disease
ENTYVIO Vedolizumab (anti-integrin α4β7)Moderately to severely active Crohn’s disease
GAZYVARO Obinutuzumab (anti-CD20) Chronic lymphocytic leukaemia
7
9
30/07/2014
14
• Manufacture, characterisation and control of the DS• Specifications• Comparability / biosimilarity• Plasma-derived medicinal products• Plasma master file• Vaccines• Stability
• Pharmaceutical Development
• Product Information
• Adventitious Agents / Viral Safety
• Transmissible Spongiform Encephalopathies (TSE)
• CJD related
• Investigational Medicinal Products
• GMO
Concept paper on review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement,
reduction and refinement) in regulatory testing of medicinal products (EMA/CHMP/CVMP/JEG-3Rs/704685/2012)
(draft for consultation until 31 May 2014)
Technical update of EMA Biological guidelines to implement best practice with regard to 3Rs:
1. Production and quality control of monoclonal antibodies and related substances
2. Potency testing of cell based immunotherapy medicinal products for the treatment of cancer
3. Production and quality control of animal immunoglobins and immunosera for human use
4. Pharmaceutical and biological aspects of combined vaccines
5. Production and quality control of cytokine products derived by biotechnological process
• EMA-FDA Pilot for QbD – Progress to Date
• Normal Operating Ranges, Proven Acceptable Ranges and Design Space (PAT Team)
• Workshop on characterisation of new clotting factor concentrates (FVIII, FIX) with respect to potency assays used for
labelling and testing of post infusion samples (held 28-29 November 2013)
• CHMP discussion on the assessment of orphan similarity. Draft template for BWP report on similarity concerning the
molecular structure